18th International Congress on Thrombosis

Abstracts

Ljubljana, Slovenia, June 20–24, 2004

Guest Editors
Mojca Stegnar, Ljubljana
Mojca Bozic, Ljubljana
Matija Kozak, Ljubljana
Polona Peternel, Ljubljana
Nina Vene, Ljubljana
Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see ‘General Information’).

© Copyright 2003 by S. Karger AG,
P.O. Box, CH–4009 Basel (Switzerland)
Printed in Switzerland on acid-free paper by
Reinhardt Druck, Basel
ISBN 3-8055-7798-2
### Contents

#### PLENARY LECTURES

<table>
<thead>
<tr>
<th>Title</th>
<th>Author(s)</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;Resistance&quot; to aspirin and other antiplatelet drugs</td>
<td>Patrono C</td>
<td>PL01</td>
</tr>
<tr>
<td>Cancer and cardiovascular disease: does a common soil exist?</td>
<td>Donati MB</td>
<td>PL02</td>
</tr>
<tr>
<td>Angiogenesis: A link to thrombosis in atherothrombotic disease</td>
<td>Conway E</td>
<td>PL03</td>
</tr>
<tr>
<td>Antiphospholipid syndrome: association between laboratory tests and clinical practice</td>
<td>Galli M</td>
<td>PL04</td>
</tr>
<tr>
<td>Coronary heart disease and inflammation - the lessons from therapeutic trials</td>
<td>Čerček B</td>
<td>PL05</td>
</tr>
<tr>
<td>Assessment of endothelial dysfunction: focus on atherothrombotic disease</td>
<td>Blann AD</td>
<td>PL06</td>
</tr>
<tr>
<td>Different locations of atherosclerosis - different risk factors, different therapies?</td>
<td>Lowe G</td>
<td>PL07</td>
</tr>
<tr>
<td>Do platelets trigger atherosclerosis?</td>
<td>Gawaz M</td>
<td>PL08</td>
</tr>
</tbody>
</table>

#### STATE-OF-THE-ART LECTURES

<table>
<thead>
<tr>
<th>Title</th>
<th>Author(s)</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombosis and stroke in neonates, infants and children</td>
<td>Nowak-Göttl U</td>
<td>SA01</td>
</tr>
<tr>
<td>Metalloproteinases in development and progression of vascular disease</td>
<td>Lijnen H</td>
<td>SA02</td>
</tr>
<tr>
<td>Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice</td>
<td>Lip G</td>
<td>SA03</td>
</tr>
<tr>
<td>Adipose tissue and atherothrombosis</td>
<td>Alessi MC*, Lijnen H, Bastelica D, Juhan-Vague I</td>
<td>SA04</td>
</tr>
<tr>
<td>Hormone replacement therapy: influence on cardiovascular disease and venous thromboembolism</td>
<td>Conard J</td>
<td>SA05</td>
</tr>
<tr>
<td>Restenosis: Lessons from therapy</td>
<td>Binder BR</td>
<td>SA06</td>
</tr>
<tr>
<td>Asymptomatic carotid stenosis: natural history and management</td>
<td>Coccheri S</td>
<td>SA07</td>
</tr>
</tbody>
</table>

#### SYMPOSIA

#### Controversies in diagnosis of VTE

<table>
<thead>
<tr>
<th>Title</th>
<th>Author(s)</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extended versus rapid analysis of the leg vein system: A multicenter ultrasound study (The ERASMUS study) - An interim analysis</td>
<td>Bernardi E on behalf of the Erasmus investigators' group</td>
<td>SY01</td>
</tr>
<tr>
<td>Can we safely exclude DVT without instrumental testing?</td>
<td>Palareti G</td>
<td>SY02</td>
</tr>
<tr>
<td>The role of helical CT in the diagnosis of pulmonary embolism</td>
<td>Huisman M</td>
<td>SY03</td>
</tr>
</tbody>
</table>

#### Signalling in platelet adhesion and aggregation

<table>
<thead>
<tr>
<th>Title</th>
<th>Author(s)</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receptor cooperation and protein phosphorylation are regulatory mechanisms of platelet recruitment.</td>
<td>Santos M*, Valles J, Moscardo A, Aznar J, Piñon M</td>
<td>SY04</td>
</tr>
<tr>
<td>ERK2 activation in collagen platelet aggregation requires cotimulation of Gi-coupled ADP receptor and Gq-coupled TXA2 receptor</td>
<td>Roger S, Mazharian A, Bryckaert M*</td>
<td>SY05</td>
</tr>
<tr>
<td>Lysosomal b-N-acetylhexosaminidase is a primer of platelet activation</td>
<td>Rossi R*, Giannini S, Mencarelli S, Falcinelli E, Orlacchio A, Emiliani C, Gresele P</td>
<td>SY06</td>
</tr>
</tbody>
</table>

#### Homocysteine

<table>
<thead>
<tr>
<th>Title</th>
<th>Author(s)</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene-gene and gene-environment interactions in mild hyperhomocysteinemia</td>
<td>D'Angelo A*, Mazzola G, Fermo I</td>
<td>SY07</td>
</tr>
<tr>
<td>Homocysteine, vitamin B6 and the risk of recurrent venous thromboembolism</td>
<td>Eichinger S*</td>
<td>SY08</td>
</tr>
<tr>
<td>Is hyperhomocysteinemia an important risk factor for cardiovascular disease?</td>
<td>Cattaneo M</td>
<td>SY10</td>
</tr>
</tbody>
</table>
How to prevent VTE recurrences

Risk factors for recurrent venous thromboembolism: the role of persistent venous obstruction
Prandoni P SY11

Low-dose warfarin
Palareti G SY12

Duration of warfarin
Agnelli G SY13

TAFl

TAFl at the interface between coagulation and fibrinolysis
Bouma B SY14

TAFl in human ischaemic stroke
Monasterio J SY15

TAFl: Molecular forms of an emerging potential risk factor for thrombotic diseases
Juhan-Vague I*, Frère C, Morange P, Alessi MC SY16

Cancer and VTE

Venous thromboembolism as a 'marker' for cancer: to screen or not to screen
Prins M SY17

Therapy of VTE in different cancer patients
Kakkar AK SY18

Biological and clinical aspects of anticancer effects of antithrombotics
Falanga A SY19

Circulating endothelial cells

Circulating endothelial cells: realities and promises in vascular disorders
Dignat-George F SY20

Circulating endothelial cells and markers of vascular damage: prognostic value
Blann AD SY21

Circulating endothelial cells in vasculitis and transplantation
Woywodt A*, Hauser H, Haubitz M SY22

Circulating endothelial cells in preclinical cancer models and in cancer patients

Management of thrombophilia

Genetics of thrombophilia
Castoldi E, Marchetti G, Bernardi F* SY24

Elevated clotting factor levels and venous thrombosis
Bertina R SY25

Management of thrombophilia: who to screen
Baglin T SY26

Thrombocytopenia

New developments in diagnosis and treatment of heparin-induced thrombocytopenia
Lubenow N SY27

Thrombocytopenia as marker of disseminated intravascular coagulation
Ten Cate H SY28

The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura
Kremer Hovinga J SY29

Factor VIII and von Willebrand factor

What is forthcoming in the treatment of hemophilia and von Willebrand disease
Lee C SY30

The value of factor VIII and von Willebrand factor as risk factors for arterial and venous thrombosis
Martinelli I SY31

ADAMTS13 deficiency: a new mechanism for arterial thrombosis?
Scheiflinger F SY32

D-dimer

Predictive value of D-dimer in recurrent deep venous thrombosis or is it time to tailor anticoagulant therapy according to values of D-dimer?
Palareti G SY33

Clinical usefulness of D-dimer in different groups of patients with suspected venous thromboembolism
Bounameaux H SY34

D-Dimer testing in pregnancy
Eichinger S SY35

Thrombolysis in PE

Thrombolysis in submassive pulmonary embolism
Büller HR SY36
**Fibrinolytic system**

The fibrinolytic system and thrombotic tendency
Kluft C

Fibrin stabilization, fibrin structure and the risk of thrombosis
Muszbek L*, Bereczky Z, Shemirani A, Katona É

New aspects in thrombosis research: possible role of complement and mast cells as profibrinolytic and antithrombotic cells

**Pharmacogenetics**

Will pharmacogenetics of antithrombotic drugs modify our approach to clinical (mega)trials?
Iacoviello L*, de Gaetano G

Cytochrome P450 2C9 (CYP2C9) polymorphism and warfarin dose requirement
Peternel P*, Herman D, Globokar T, Stegnar M, Dolžan V

Antithrombotic efficacy of aspirin and genetic polymorphisms in the hemostatic system
Musial J*, Szczeklik A, Undas A, Sanak M

**Virchow’s triad revisited**

The blood vessel wall
Blann AD

Virchow’s triad revisited: blood constituents
Lip G

Virchow’s triad revisited: abnormal flow
Lowe GDO

**Prophylactic treatment of VTE**

Assessment of the risk for prophylactic treatment of venous thrombo-embolism in medical patients
Samama MM*, Gertotziafas G, Horellou M, Elalamy I, Conard J

Assessment of the risk and the prophylaxis of venous thromboembolism in surgical patients
Bergqvist D

Assessment of the risk and prophylactic treatment of venous thromboembolism in pregnancy
Conard J*, Horellou M

Assessment of the risk and prophylactic treatment of venous thromboembolism in the elderly
Couturaud F

**Oral anticoagulant therapy**

Warfarin management in difficult situations
Palareti G

Computer assisted anticoagulant therapy
Manotti C

Self adjustment of oral anticoagulant therapy
Watzke H

**Dietary interventions**

Mediterranean diet: is all the secret in oil?
Serra-Majem L

The Mediterranean lecture: wine and thrombosis - from epidemiology to physiology and back
de Gaetano G

Adherence to Mediterranean diet and coronary heart disease
Trichopoulou A

**New antithrombotic strategies**

Platelet proteomics: identification of potential therapeutic targets
Maguire P*, Fitzgerald D

Peptidomimetic inhibitors of thrombin
Kikelj D

Antithrombotic effects of statins
Tremoli È*, Colli S, Mussoni L, Sironi L, Banfi C, Camera M

Synthetic Factor Xa inhibitors
Samama MM*, Gerotziafas G

**The CLAHT symposium**

Role of transfusion programs in stroke prevention in susceptible sickle cell children

Haemostatic cardiovascular risk factors: differential effects of red wine and diet on healthy young population
Mezzano D*, Leighton F*

Management of patients with acute venous thromboembolism: Findings from the RIETE Registry

**ORAL COMMUNICATIONS**

Coronary artery disease

Polymorphisms on thrombospondin genes and premature acute myocardial infarction: a controversy to settle
Emerging prognostic factors in coronary artery disease

Increased plasma concentration of platelet-derived microparticles in young survivors of myocardial infarction
Michelsen A*, Brodin E, Brosstad F, Hansen J

Gene-gene interaction of the ABCA1 transporter and paraoxonase genes in inherited predisposition to myocardial infarction in young men
Pchelina S*, Sheydaia A, Taraskina A, Rodygina T, Schwarzman A

Circulating endothelial cells predict outcomes in patients with acute coronary syndrome: relationship to plasma von Willebrand factor and interleukin-6
Lee W*, Lıp G

Hematological malignancies
Thrombosis of splanchnic veins in patients with silent myeloproliferative disorders
Miljic P*, Sefer D, Sretenovic M, Suvađzic N, Colovic M

A prospective observational study on catheter-related complications in patients with hematological malignancies (CATHEM)

Proteolysis of von Willebrand factor increases in children during the induction therapy for acute lymphoblastic leukemia

Factor XIII activity levels in acute leukemia

Alterations of coagulation pathway parameters in children with acute lymphoblastic leukaemia (ALL)

Coordinated dysregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute leukemia

Animal experimental models
Platelets migrate in response to allergen in vivo and in vitro: role of IgE
Pitchford S*, Momi S, Casali L, Gresele P

Successful inhibition of venous thrombus growth after oral administration of BAY 59-7939, a direct Factor Xa inhibitor in rabbits
Biemand BJ*, Friederich PW, Levi M, Perzborn E, Buetethorn U, Bülker H

Increased pulmonary expression of thrombin receptor in rabbits with endotoxin-induced acute lung injury

PPAR-alpha deficiency does not modify age dependent but prevents high fat diet increase in plasma PAI-1 as well as insulin resistance
Mavri A, Bastelica D, Steals B, El Ayachi S, Juhan-Vague I, Alessi MC

Suitability of selected clotting assays to explain antithrombotic potential of LK732, argatroban and nadroparin in rat venous thrombosis model

VTE prophylaxis
Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III Study
Schulman S*, Lundström T, Wahlander K, Billing Clason S, Eriksson H, for the THRIVE III

The development in attitudes towards thromboprophylaxis in Danish surgical departments during a twenty year period
Rasmussen M*, Wegner L, Wilke-Jørgensen P

Practice variation in USA and Europe for the prevention of venous thromboembolism in hospitalized medical patients: Findings from IMPROVE
Deep vein thrombosis prophylaxis following arthroscopy, lower limb fractures, and in patients in plaster casts. Results of a survey
Dentali F*, Ageno W, Imberti D

Cancer and thrombosis
Nitric oxide levels and its relevance to C-reactive Protein, CD 40L, TF and TNF-alpha in malignancy associated hypercoagulable state

Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma
Caine G, Lip G, Stonelake P, Ryan P, Blann AD*

Lower APCR correlates with apoptotic activation of CD8+T cells in non-small cell lung cancer

A double-blind placebo-controlled randomized study on enoxaparin for the prevention of upper limb DVT in cancer patients with CVC

Comparison of incidence between thromboembolic events (TEs) and malignancies. An epidemiological retrospective study
Roldan V, Martin F, Garcia A, Marco P, Sogorb F, Lip G*

Home treatment of cancer patients with deep venous thrombosis

Fibrinolysis
The influence of long-term glycemic control on fibrinolytic activity in type-1 diabetic patients
Seljeflot I*, Larsen J, Dahl-Jørgensen K, Hanssen K, Arnesen H

The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus
Guldiken S, Turgut B, Demir M*, Arikan E, Kara M, Tugrul A, Vural O

Phospholipids retard fibrinolysis
Kolev K*, Vărădi B, Tenekedjiev K, Machovich R, Longstaff C

Impaired fibrinolysis among women with premature Peripheral artery occlusive disease (PAD)

Plasminogen activator inhibitor-1 gene polymorphism (-675 4G/5G) associated with obesity
Özel D*, Berberoğlu M, Akar E, Akar N

Expression and localization of uPA, PAI-1 and PAI-3 in primary breast cancer

Cardiovascular disease
Serum osteoprotegerin (OPG) levels are decreased in subjects with calcified carotid artery plaques
Mathiesen E*, Vik A, Sveinbjörnsso B, Notø A, Hansen J

Markers of endothelial damage and inflammation correlate with a point-based score for stroke risk in atrial fibrillation
Roldan V, Martin F, Garcia A, Marco P, Sogorb F, Lip G*

Associations of plasma fibrinogen, viscosity, D-dimer and tPA with risk of recurrent strokes in the PROGRESS study
Rumley A, Woodward M, Lowe G*

Plasma angiopoietins 1 and 2, and angiopoietin receptor TIE-2 in congestive heart failure
Blann AD*, Chong AY, Freestone B, Lip G

Increased circulating endothelial cells as an index of endothelial damage in congestive heart failure
Blann AD*, Chong AY, Freestone B, Lip G

Association between obesity, fatty liver and fibrinogen as related to coronary artery disease in sample of the middle-aged urban population
Bogdanov M*, Virc-Bogdanov S

Platelets I
Molecular defects in Tunisian families with Glanzmann thrombasthenia

Activation of platelets exposed to shear stress with smoke extracts of high-nicotine and zero-nicotine cigarettes: the protective effect of nicotine
Jesty J*, Ramachandran J, Bluestein D

Platelets express surface CD40L upon interaction with damaged vessel wall in vivo in humans: effects of aspirin intake
Giannini S*, Rossi R, Guzzetta M, Falcinelli E, Ongini E, Gresele P

Ongoing prothrombotic state in patients with hypercholesterolemia: role for soluble CD40 ligand and oxidative stress
Aspirin resistance and prognosis in the setting of non st elevation acute coronary syndromes
Perdou A*, Zairis M, Tsiribis V, Patsourakos N, Lytras A, Fouskas S, Tsoukanas K

Application of the cone and plate(let) Analyzer for testing the response to aspirin treatment
Spectre G*, Brill A, Gural A, Turetzky N, Mosseri E, Savion D, Varon D

Antiphospholipid syndrome

Regulation of NF-kB activation in the anti-phospholipid syndrome: involvement of ERK1/2 and p38 MAP kinase pathways

Platelet deposition under flow condition is increased in patients with antiphospholipid syndrome who experience thrombotic events
Shenkman B, Levi Y, Tamarin I, Savion N, Shoensfeld Y, Varon D

Laboratory diagnosis of antiphospholipid syndrome: difficulties and possibilities
Makatsaria A*, Khizroeva D, Bitsadze VO, Baimuradova SM

Elevated levels of prothrombin fragment 1+2 in patients with antiphospholipid antibodies but without clinical signs of antiphospholipid syndrome
Ambrožič A*, Božič B, Rozman B

Detection of antiphospholipid antibodies (APAs) in patients with autoimmune and thrombotic diseases
Nagy E*, Sallai K, Gergely P, Bodó I

A survey on diagnosis of lupus anticoagulant among laboratories of the Italian Federation Of Anticoagulation Clinics (FCSA)

VTE – Clinical aspects I

Objective assessment of deep vein thrombosis and pulmonary embolism can be deferred without increased risk of thrombosis

Value of D-dimer, for the exclusion of deep venous thrombosis, in the low-moderate and high pre-test probability groups
El Kheir D*, Gerdes V, Büller HR

Residual post treatment ultrasound detected thrombosis is associated with an increased risk of recurrence
Young L, Ockelford P*, Rolfe-Vyson V, McKelvie S, Harper P

The long-term clinical course of acute deep vein thrombosis of upper extremities. A prospective cohort study

Chronic renal failure: thrombotic events and relation with the levels of thrombomodulin, TFPI and von Willebrand factor

Venous thromboembolism and spinal surgery

Direct thrombin inhibitors

Efficacy and safety of ximelagatran for prevention of thromboembolism using the EXPRESS regimen across different orthopaedic surgery patient groups

Dabigatran etexilate, new oral direct thrombin inhibitor, in the prevention of thromboembolic events after total hip/knee replacement: BISTRO-2 Study

Influence of time of first dose on the efficacy and safety of postoperative ximelagatran for prevention of thromboembolism after orthopaedic surgery

Timing of initiation of thromboembolism prophylaxis in total hip/knee replacement with dabigatran etexilate, a new oral direct thrombin inhibitor

Ximelagatran/melagatran versus LMWH in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration
Zufferey P, Laporte S, Quenet S, Mollieux S, Auboyer C, Decousus H, Mismetti P* 

LMWH or ximelagatran versus VKA in the prevention of VTE after major knee surgery: a meta-analysis of randomized controlled trials
Iorio A*, Ferrante F, Nenci G

Haemophilia

A familial multi-vitamin K-dependent syndrome associated with compound heterozygosity in the gamma-glutamyl carboxylase gene
Hemophilic arthropathy: A comparison between the findings of magnetic tomography and of simple X-rays
Makris P*, Haritanti A, Fotiadis N, Girtovitis F, Dimitriadis A

Successful treatment of spontaneous intracerebral haemorrhage in a patient with prosthetic mechanical heart valves
Iorio A*, La Torre D, Conti S, Gambelunghe G

Deficient platelet response to collagen: involvement of the glycoprotein VI mediated signaling pathway in two patients
Bellucci S, Huisse M, Boval B, Robert A, Fauvel-Lafeve F, Jandrot-Perrus M

Reticulated platelets: a reliable parameter to reduce prophylactic platelet transfusion after autologous bone marrow transplantation
Chaoui D, Robert F, Chakroun T, Rio B, Ramdane B, Lecrubier C, Casadevall N, Marie J, Elalamy I*

Platelets II

Determination of platelet derived microparticles in patients with autoimmune trombocytopenia
Hlusí A, Slavík L*, Krcova V, Pikalova Z

The new mutation in the GP IIa gene associated with high platelet aggregation is found in Russia
Sirotkina O*, Sheydina A, Vavilova T, Schwarzman A

17 beta-oestradiol potentiates thrombin and tromboxane-dependent platelet aggregation and exposition of fibrinogen binding sites on platelet surface
Petrapiána D*, Moro L, Reineri S, Piranda D, Bordone R, Bertoni A, Torti M, Simigaglia F

Metabolic syndrome

Prothrombotic risk in hypertensives with metabolic syndrome

Prognostic role of fibrinogen and D-dimers in diabetic polyvascular disease?
Bosevski M*, Kostoska S, Tosev S, Meskoska S, Borozanov V, Georgievská L, Peovska I

Do plasma levels of angiogenic factors reflect vitreous levels in patients with proliferative diabetic retinopathy?
Ghosh Y, Reginald A, Banerjee S, Dhingra S, Tyagi A, Lip G*

Plasma vascular endothelial growth factor and angiopoietins in diabetes is related to endothelial damage/dysfunction and atherosclerosis
Lim S*, Blann AD, Lip G

Soluble CD40 Ligand, Interleukin-6 and Tissue Factor in Diabetes and the Effect of Intensive Multi-Factorial Intervention
Lim S*, Blann AD, Lip G

Increased intima-media thickness of carotid arteries in women with previous gestational diabetes mellitus
Janša K*

Influence of oxidatively modified fibrinogen on platelet function
Dyr JE*, Vanickova M, Suttner J

Pregnancy I

Markers of haemostatic activation in pregnant women with deep-vein thrombosis
Božič M*, Antolič B, Peternel P, Šajina-Stritar B, Stegnar M

Retrospective analysis of thrombophilic parameters in women with adverse pregnancy outcome

Venous thromboembolism after elective cesarean section
Jacobsen A*, Drolsum A, Kløw N, Dahl G, Qvigstad E, Sandset P

Placental vascular abnormalities in neonatal alloimmune thrombocytopenia (NAIT)
Weir E*, Althaus J, Blakemore K, Askin F, Kickler T*

Rationalising of diagnostic management of pulmonary embolism in pregnancy: fetal radiation exposure in radiologic procedures

Increased titer of antiphospholipid antibodies in women with high risk pregnancy
Hoppensteadt D*, Cunanan J, Opaktek A, Fareed J
VTE – Clinical aspects II

Inherited protein S deficiency type I, but not type III is a risk factor for venous, but not arterial thrombosis; a study in 81 families
Brouwer JLP*, Veeger N, van der Schaaf W, Kluin-Nelemans H, van der Meer J

Markers of inflammation, D-dimer and recurrences after a first episode of venous thromboembolism
Cosmi B*, Legnani C, Guazzaloca G, Coccherti S, Palareti G

Success of initiatives to familiarize vascular physicians in Germany with outpatient treatment of deep venous thrombosis
Werner B*, Jürgen D, Horst E G

Cost-effectiveness of bemiparin in the acute and long-term treatment of deep vein thrombosis
Rocha E, Gómez-Outes A*, Martínez-González J*, Kakkar V

Outpatient tinzaparin therapy in 102 patients with pulmonary embolism - final results
Olsson*, Bajc M, Bitzén U, Carlsson MS, Elf J, Jönsson K, Magnusson P, Olsson B, Jonson B

Analysis of predisposing factors and 6 month outcomes of DVT management in 668 patients treated with LMWH(tinzaparin) as outpatients
Rhodes S, Bond S*, Green E

Genetic Polymorphisms

Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis
Uitte de Willige S*, van Marion V, Rosendaal F, Vos H, de Visser M, Bertina R

Expression and characterization of a new factor V mutation (R1698W) found in combination with FV Leiden
Lunghi B, Scanavini D, Ulazzi L, Busani C, Redaelli R, Tagariello G, Bernardi F*

Genetic markers of inflammation and sensitivity to activated protein C (APC)
González-Ordóñez A*, Macias D, Arias A, Fernández-Carreira JM, Morán M, Peliz M, Martin L

Frequency of cytochrome CYP2C9 polymorphism in Russian Population and it effects in 62 patients treated by warfarin
Vavilova T*, Sirotkina O, Ulitina A, Kadinskaya M, Schwarzman A

TNFRI +36 G/G genotype and the metabolic syndrome both predispose obese women to higher levels of soluble TNFRs, PAI-1 and liver enzymes
Mavri A, Bastelica D, Saut N, Verdier M, Renucci J, Juhan-Vague I, Alessi MC

Fibrinogen polymorphisms Taq I, Hae III and Bcl I are not major risk factors for deep-vein thrombosis
Božič M*, Teran N, Peterlin B, Stegnar M

Ischaemic stroke

Inherited risk factors for ischemic stroke
Sirotkina O*, Tcherkas Y, Elchaninov A, Merkulova A, Chukhlovdina M, Denisenko A, Schwarzman A

Inherited prothrombotic risk factors (factor V G1691A, factor II G20210A, MTHFR C677T and platelet polymorphisms) in pediatric ischemic stroke
Oliveira L, Ozelo M, Rossi F, Annichino-Bizzacchi JM*, Moura-Ribeiro M, Castro V

Congenital thrombophilia in patients with cerebral ischemia and patent foramen ovalis (PFO)

Lipoprotein(a) and C-reactive protein in children with cerebrovascular Events
Zrinski Topić R, Coen D*, Fuček M, Mišoš M, Leniček-Križa J, Dodig S

Genetic determinants of hyperhomocysteinemia in ischemic stroke: The role of MTHFR (C677T and A1298C), TSER and MTR A2756G
Kim N*, Oh D, Park S

Is thrombin activatable fibrinolysis inhibitor a contributing factor for development of thrombotic complications in patients with ischemic stroke?

Oral anticoagulant treatment I

Bleeding complications of oral anticoagulation therapy: a prospective audit
Bond S*, Rhodes S, Green E, James R, Taylor M, Rose P, Emmas C

The relationship of D-dimer and residual vein thrombosis as risk factors for recurrent venous thromboembolism after anticoagulation withdrawal
Cosmi B*, Legnani C, Cini M, Guazzaloca G, Palareti G

Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin
Gasse C*, Hollowell J, Meier C, Troost J, Schneider V, Haefeli W

The effect of vitamin K substitution on anticoagulant treatment
Rombouts E*, Van der Meer F, Rosendaal F

Telemedicine for managing patients on oral anticoagulant therapy

X
Pathophysiol Haemost Thromb 2003; 33 (suppl2)
| OC114 | Monitoring low molecular weight heparin in pregnancy: the timing of the peak measurement | Shiach C*, Johnston T |
| OC115 | Postthrombotic syndrome |
| OC116 | Do vena cava filters increase the incidence of post-thrombotic syndrome? Results from the eight-year follow-up of the randomised PREPIC trial |
| OC117 | Postoperative asymptomatic deep vein thrombosis and the development of postthrombotic syndrome: A systematic review |
| OC118 | Inter-observer variables in results of compression ultrasonography performed in acutely ill medical patients |
| OC119 | Factors predicting long-term venous thrombotic complications after insertion of vena cava filters: results of the randomised PREPIC trial |
| OC120 | Elastic stockings, hydroxyethylrutosides or both for the treatment of the post-thrombotic syndrome. A pilot randomized study |
| OC121 | Pregnancy II |
| OC122 | Factor V Leiden, prothrombin G20210A and MTHFR C677T mutations in women with abruptio placenta |
| OC123 | Safety and efficacy of nadroparin for the treatment or prophylaxis venous thromboembolism in pregnancy |
| OC124 | APC-NR and PC-NR as markers of prethrombotic changes in pregnancy |
| OC125 | Monitoring low molecular weight heparin in pregnancy |
| OC126 | Oral anticoagulant treatment II |
| OC127 | Upper gastrointestinal hemorrhage, anticoagulant therapy and nonsteroidal antiinflammatory drugs - results of a prospective study |
| OC128 | Patients on oral anticoagulant treatment: anticoagulation clinic vs assistant physician |
| OC129 | Efficacy and risk of anticoagulant therapy in 102 patients with thrombosis and cancer |
| OC130 | Vitamin K antagonists are less prescribed in outpatients with permanent lone atrial fibrillation: results of a large observational survey in France |
| OC131 | Residual vein thrombosis assessment establishes the optimal duration of anticoagulants in patients with idiopathic or provoked deep vein thrombosis |
| OC132 | Comparative effects of antiplatelet, anticoagulant or combined therapy in patients with valvular and non-valvular atrial fibrillation |
| OC133 | Hyperhomocysteinemia |
| OC134 | Gene polymorphisms (C677T and A1298C MTHFR, A2756G MTR and 844ins68 CBS) in atrial fibrillation |
| OC135 | Homocysteine, vitamins and C-reactive protein in the InCHIANTI Study |
**Absolute risk of venous and arterial thromboembolism associated with mild hyperhomocysteinemia**
van de Poel M*, Libourel E, Bank I, Middeldorp S, Hamulyak K, Prins M, Büller HR, van der Meer J

**Methionine loading test affects thrombin generation in high risk patients**
Domagala TB*, Undas A, Celinska-Lowenhoff M, Rybak M, Szczeklik A

**Hyperhomocysteinemia in cancer patients with thrombosis is independent of methylene tetrahydrofolate reductase gene mutation**
Cunanan J*, Tubo M, Iqbal O, Demir M, Fareed J, Deitcher S

**Methionine loading test affects thrombin generation in high risk patients**
Domagala TB*, Undas A, Celinska-Lowenhoff M, Rybak M, Szczeklik A

**Hyperhomocysteinemia in cancer patients with thrombosis is independent of methylene tetrahydrofolate reductase gene mutation**
Cunanan J*, Tubo M, Iqbal O, Demir M, Fareed J, Deitcher S

**Metalloproteinases**

**Circulating tissue inhibitor of metalloproteinase-1 elevation correlates with impaired diastolic relaxation in patients with hypertension**
Tayebjee M*, Nadar S, MacFadyen R, Lip G

**Circulating MMP-9, TIMP-1 and TIMP-2 in gestational hypertension**
Tayebjee M*, Karalis I, Nadar S, Beevers DG, MacFadyen R, Lip G

**Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension: Relationship to cardiovascular risk and treatment**
Tayebjee M*, Nadar S, Blann AD, Beevers DG, MacFadyen R, Lip G

**Correlation of protein and mRNA expression of fibrinolytic and matrix metalloproteinase systems in endometriosis**

**Popliteal arterial aneurysm - the role of proteolytic enzymes**
Kozak M*, Štalc J, Tominc U

**The roles of serum matrix metalloproteinases in patients with post myocardial infarction to heart failure**
Jong G*, Ma T, Kuo S

**Heparins**

**Managed hemostasis “point-of-care” testing in a large hospital: a three-year experience and the assessment of clotting tests**

**Once-daily LMWH versus UFH for the treatment of acute venous thromboembolism: a non-inferiority meta-analysis**

**Therapeutic implications of product individuality in commercially available low molecular weight heparins and their generic versions**

**Evaluation of the effectiveness and safety of bemiparin, a second-generation low-molecular-weight heparin, in several orthopaedic settings**

**Bemiparin prospective observational study on the prevention of venous thromboembolism in medical patients**
Gómez-Outes A, Martínez-González J*, Maeso R, García-Hernández A

**Low-molecular-weight heparin causes less heparin-induced antibodies than unfractionated heparin: A prospective study in neurologic patients**
Harbrecht U*, Andrea K, Britta B, Peter H, Thomas K, Christoph P

**Thrombophilia**

**Factors I, VII, VIII, IX, X and XI levels and the risk of deep venous thrombosis**
Mello T, Machado T, Ozello M, Annichino-Bizzacchi JM*

**High factor VIII (FVIII) levels in venous thromboembolism: role of the unbound component of FVIII**

**The relationship between inherited thrombophilia and residual vein thrombosis as risk factors for recurrent venous thromboembolism**
Cosmi B*, Legnani C, Cini M, Guazzaloca G, Palareti G

**Retinal vein thrombosis and thrombophilic risk factors**

**Risk factors for CNS thrombosis in neonates and children**
Pergantou H*, Kapsimali Z, Adamitzki E, Platokouki H, Vranou M, Aronis S

**Coagulation activation in patients with and without thrombophilia during anticoagulant treatment for venous thrombosis**
Vižintin Cuderman T*, Božič M, Peternel P, Stegnar M

**TAFI**

**A new TAFI antigen assay independent of polymorphism 325Thr/Ille and147 Ala/Thr**
Cost H, Grimaux M, Grosley M, Woodhams B*
Influence of the Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Thr325Ile polymorphism on TAFI levels determined with three new assays
Frère C, Aillaud MF, Saut N, Grosley M, Beltran J, Juhan-Vague I, Alessi MC

TAFI levels in patients with acute myocardial infarction treated with thrombolysis

Mediation of fibrinolytic deficit in cancer patients by plasminogen activator inhibitor-1 and thrombin activatable fibrinolytic inhibitor
Florian-Kujawski M*, Hoppensteadt D, Iqbal O, Demir M, Tobu M, Fareed D, Fareed J

Modulation of thrombin activatable fibrinolytic inhibitor (TAFI) by heparins: Variation among normal and patient populations

Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to hemostatic complications in patients with different types of brain injury?

FEATURED POSTERS

Cardiovascular disease I

Abnormal heart rate variability is associated with platelet activation in stable coronary disease during recovery from myocardial infarction
Hamaad A*, Blann AD, Lip G, MacFadyen R

Abnormalities in heart rate variability is associated with platelet activation in acute ST-elevation myocardial infarction
Hamaad A*, Blann AD, Lip G, MacFadyen R

EPCR 23 bp Insertion in Atherosclerosis and Early MI
Ulu A*, Akar R, Emiroglu O, Ucanok K, Akar E, Akar N

Soluble tissue factor in plasma from patients with acute myocardial infarction is not microvesicle associated
Seljeflot I*, Lyberg T, Arnesen H

The effects of home-based versus hospital-based cardiac rehabilitation on plasma haemostatic markers in patients with coronary heart disease
Lee W*, Jolly K, Lip G

Anticoagulant therapy

Hemostatic markers in patients with chronic atrial fibrillation - relationship to thromboembolic risk
Vene N*, Mavri A, Košmelj K, Stegnar M

Methods in coagulation

Anti-Xa activity monitoring of the synthetic pentasaccharide Fondaparinux
Van Dreden P*, Fontaine S, Woodhams

The Ecarin Chromogenic Assay (ECA) for quantitative determination of direct thrombin inhibitors-From a routine method to a point-of-care test
Lange U*, Frische I, Olschewski A, Nowak G, Buch E

Cardiovascular disease II

Dietary habits and their role on the occurrence of coronary artery disease: is the Italian a real Mediterranean-diet?

Oxidative stress—a link between endothelial injury, coagulation activation and atherosclerosis in haemodialysis patients
Pawlak K*, Naumnik B, Brzosko S, Pawlak D, Mysliwiec M

Anticoagulation in conventional versus transesophageal echocardiography guided cardioversion of atrial fibrillation
Dokler Glavnik A*, Žohar P*, Gunzek R*, Bervar M*, Marinšek M*, Kralj Močnik F*

Low molecular weight heparin limits prothrombotic reactions and may shorten in-hospital stay of patients with heart failure
Wachnicka-Truty R*, Birkholz-Golaszewska A, Korzeniowski A, Flasiński J, Górski J

Replacing acenocoumarol with the low molecular weight heparin Tinzaparin sodium in patients undergoing general surgery operations: a pilot study

Oral Anticoagulant Therapy Management In Patient Self-Testing
Testa S*, Alatri A, Morstabilini G

A novel assay for tissue factor pathway inhibitor (TFPI) anticoagulant activity in plasma
Dahm A*, Andersen T, Rosendaal F, Sandset P

A novel coagulation assay used to detect procoagulant phospholipid correlates with microparticle numbers in resting and collagen-stimulated samples
Connor D*, Exner T, Ma D, Joseph J*

Von Willebrand factor cleavage in vitro at room temperature occurs without the need for divalent ions
Perutelli P*, Amato S, Molinari A

的方法

Anti-Xa activity monitoring of the synthetic pentasaccharide Fondaparinux
Van Dreden P*, Fontaine S, Woodhams

The Ecarin Chromogenic Assay (ECA) for quantitative determination of direct thrombin inhibitors-From a routine method to a point-of-care test
Lange U*, Frische I, Olschewski A, Nowak G, Buch E

A novel assay for tissue factor pathway inhibitor (TFPI) anticoagulant activity in plasma
Dahm A*, Andersen T, Rosendaal F, Sandset P

A novel coagulation assay used to detect procoagulant phospholipid correlates with microparticle numbers in resting and collagen-stimulated samples
Connor D*, Exner T, Ma D, Joseph J*

Von Willebrand factor cleavage in vitro at room temperature occurs without the need for divalent ions
Perutelli P*, Amato S, Molinari A

Methods in coagulation

Anti-Xa activity monitoring of the synthetic pentasaccharide Fondaparinux
Van Dreden P*, Fontaine S, Woodhams

The Ecarin Chromogenic Assay (ECA) for quantitative determination of direct thrombin inhibitors-From a routine method to a point-of-care test
Lange U*, Frische I, Olschewski A, Nowak G, Buch E

A novel assay for tissue factor pathway inhibitor (TFPI) anticoagulant activity in plasma
Dahm A*, Andersen T, Rosendaal F, Sandset P

A novel coagulation assay used to detect procoagulant phospholipid correlates with microparticle numbers in resting and collagen-stimulated samples
Connor D*, Exner T, Ma D, Joseph J*

Von Willebrand factor cleavage in vitro at room temperature occurs without the need for divalent ions
Perutelli P*, Amato S, Molinari A
NCX 6550, a nitric oxide (NO)-releasing derivative of pravastatin, exerts antiplatelet and antithrombotic activity
Momi S*, Rossiello M, Caracchini R, Monopoli A, Ongini E, Gresele P, Colucci M

FP18 Abstract withdrawn

Lipoproteins

Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors
Sebeščjen M*, Keber I, Žegura B, Simčič S, Božič M, Migaud Fressart M, Stegnar M

FP31

Maximal doses of Atorvastatin improve inflammation, thrombogenesis and matrix remodelling in high-risk ischaemic heart disease patients
Marin F, Roldan V, Garcia-Herola A, Lorenzo S, de Teresa L, Sogorb F, Lip G*

FP32

Short-term nonlipid effects of simvastatin and micronised fenofibrate in high risk patients
Celińska-Lowenhoff M*, Undas A, Iwaniec T, Szczeklik A

FP33

Interactions between tissue factor pathway inhibitor (TFPI) and lipoprotein lipase (LPL) in the metabolism of triglyceride-rich lipoproteins
Brodin E*, Iversen N, Hansen J

FP34

Delayed postprandial clearance of chylomicrons and increased ApoC-I in plasma VLDL in patients with echolucent carotid plaques
Nouts A*, Mathiesen E, Björkengren J, Hansen J

FP35

Platelets

Influence of antiplatelet therapy on platelet-mediated thrombin generation after carotid stenting
Piñon M*, Valles J, Santos M, Lago A, Tembl J, Aznar J, Moscardo A

FP21

Role of PECAM-1 in acutely formed platelet thrombi during human microvascular anastomosis
Olsson E*, Sarlomo-Rikala M, Böhlind T, Lassila R

FP22

Effects of CML Drugs (taxol, rapamycin and glivec) on Platelet Aggregation and on Fibrinogen Binding to Platelets
Tetik S*, Eksioglu-Demiralp E, Yardimci T

FP23

The Release of Matrix Metalloproteinase-9 in Human Platelets: Regulation of Platelet Activation in In Vitro and In Vivo Studies
Sheu J*, Shen M, Hsiao G

FP24

Is assay of fibrin gel permeability a precise way to determine the effects of acetylsalicylic acid on coagulation?

FP25

VTE

Plasma levels of Factor VIII, IX and XI and Risk of Recurrent Venous Thromboembolism

FP26

The value of compression ultrasound in diagnosis of asymptomatic deep venous thrombosis in acutely ill medical patients

FP27

High incidence of symptomatic chronic thromboembolic pulmonary hypertension after symptomatic pulmonary embolism

FP28

Observational study of bemiparin, first dose administered 6 hours after surgery, in hip or knee replacement surgery

FP29

Comparative anticoagulant and antiprotease actions of BAY 59-7939 - an oral, direct Factor Xa inhibitor - and enoxaparin and fondaparinux
Hoppensteadt D*, Neveille B, Maddenini J, Perzborn E, Misselwitz T, Fareed J

FP39

Influence of prognostic factors on the risk of recurrence or bleeding in long-term secondary prevention of venous thromboembolism with ximelagatran
Eriksson H*, Lundström T, Wåhlander K, Billing Clason S, Schulman S, for the THRIVE III I

FP37

Phase I double blind, placebo controlled, ascending single intravenous dose study with a synthetic direct thrombin inhibitor, TGN255
Combe S*, Allen G, Kennedy T

FP38

Comparative anticoagulant and antiprotease actions of dabigatran in patients undergoing total hip or knee replacement in BISTRO-2

FP40
Cancer

Effect of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer
Caine G, Harris A, Christodoulou K, Lip G, Blann AD

Intrinsic “tenase” and prothrombinase activity of t-lymphoblastoid cells is enhanced by lipid peroxidation
Pickering W*, Gray E, Goodall A, Barrowcliffe T

Upregulation of monocyte chemotactic protein-1 and CD40 ligand in cancer patients and their modulation by subcutaneous enoxaparin
Fareed J*, Tobu M, Demir M, Hoppensteadt D, Deitcher S

Platelet-derived vegf, flt-1, angiopoietin-1 and p-selectin in breast and prostate cancer
Caine G, Lip G, Blann AD*

Optimal dosing of bemiparin for the prevention of venous thromboembolism in surgery for cancer
Gómez-Outes A, Martínez-González J*, del Campo J, Rocha E*

POSTERS

Cardiovascular disease

Ischaemic cardiopathy and associated risk factors in two elderly women groups of low socio-economic condition

Factors that may influence in the adequate control of arterial hypertension

Coronary heart disease estimation in an elderly population

Prothrombotic risk in white coat hypertensives
Theodossiades G*, Vyssoulis G, Karpanou E, Zervoudaki A, Tsevrenis V, Kokkinos D, Stefanidis C

Pathogenic role of nitric oxide in thromboembolic complications in patients with chronic heart failure
Mirsamatova G

A comparison between intima-media thickness and coronary artery disease

The effects of incremental shuttle walking on activation of haemostatic and haemorheologic markers in patients with coronary heart disease
Lee W*, Ingram J, Jolly K, Lip G

Use of low-molecular-weight-heparin in early cardioversion
Dokler Glavnik A*, Škrabl Močnik F, Žohar P, Bervar M, Marinšek M, Gunzek R

Left ventricular diastolic dysfunction is associated with abnormal haemorheology, thrombogenesis and endothelial damage/dysfunction
Lee W*, Lip G

Fluid shear stress, blood coagulation and epigenome topography of granulocytes nuclei at atherosclerosis: what is evident?
Teplyakov A

New polymorphism in the first intron of the ABCA1 transporter gene
Sheydnina A*, Pchelina S, Demina E, Schwarzman A

Enhanced level of tissue-type plasminogen activator antigen in hypertensive small deep infarcts
Ionova V*, Suslina Z, Maximova M, Tanashian M, Klimovich L

Hyperhomocysteinemia is significant risk factor for cerebral arterial occlusive diseases in North West Russia
Shmeleva V*, Kapustin S, Papayan L

Oral methionine load induces von Willebrand factor changes in women with peripheral occlusive disease
Peutelli P*, Amato S, Bottini F, Miniti G, Cerone R, Molinari A

Analysis of 5 SNPs of the ABCA1 gene in patients with ischemic stroke
Taraskina A, Sheydnia A*, Sirotkina O, Elchaninov A, Pchelina S

ASO titer and efficacy of streptokinase in acute myocardial infarction patients
Ostovan M*, Hooshmand S

Lympocyte platelet adhesion in acute coronary syndrome
Solpov A*, Govorin A, Gorbunov V, Vitkovsky Y

Different molecules of endothelial origin - master of cytokines network balance: new evidence of lymphocytes functioning at atherosclerosis
Teplyakov A*


Coagulation factors and inhibitors

Protein C as diagnostic marker in early diagnosis of severe intra-abdominal infections Vukosavljević D*, Vodnik T, Majkić-Singh N, Karamarković A

Is factor VII deficiency predisposing to foetal loss? (Study of a large family) Lo Pinto G*, Perroni L, Cusano R, Barbaresi M, Costa M, Malatesti V


A proteomic approach for the resolution of vitamin K dependent proteins Uras F*, Salim Dalgıç A, Uras A

Factor XIII Val34Leu polymorphism as a modulator of resistance to fibrinolysis in subjects treated with aspirin Undas A*, Brožek J, Iwaniec T, Szczeklik A

Factor VII activity and blood coagulation at the site of microvascular injury Brzezinska B, Undas A, Padjas A*, Iwaniec T, Musiał J

Role of fibrin in thrombin behavior de Bosch N

Factor XIII level and prevalence of FXIII-A Val34Leu polymorphism in patients with peripheral arterial disease and Raynaud's disease Shemirani A*, Csiki Z, Szomják E, Katona É, Bereczky Z, Muszbek L

Factor XIII subunit B: a protein A-binding protein Kerényi A*, Harmács G, Muszbek L

Effect of short wave frequency electromagnetic radiation on lymphocyte-platelet adhesion and tissue factor expression by leukocytes Nardina I*, Vitkovsky Y

FVIII Levels During Attacks of Familial Mediterranean Fever Akar N*, Ekim M, Gürgan C

Successful use of recombinant activated factor VII (rFVIIa) in a patient with severe bleeding during transabdominal retropubic prostatectomy Monteiro C*, Jorreto M, Gonçalves L, Fraga M, Pereira R

Tensile strength of blood clot Savushkin AV*

Blood clot: hydraulic resistance and its changing Savushkin AV*

Erythrocyte desert out the blood clot phenomenon (filtration "back to front") Savushkin AV*

Anticoagulant therapy

Warfarin is superior to Acenocoumarol in the management of patients requiring low doses of oral anticoagulants Ceresetto JM*, Rabinovich O, Stemmelin G, Shanley C, Dubosq C, Gutierrez M, Mendizabal G, Doti C, Vicente M, Bullorsky E

Validation of CoaguChek S on samples of patients on stable oral anticoagulation Laszlo P*

Dental surgery in patients treated with oral anticoagulants Dimova C*, Kostovska S, Dejanova V, Kovacevska I, Andonovska B

Evaluating the interaction of allopurinol with the oral anticoagulants Rodrigues*, Martins R, Viegas E

Recurrence of deep vein thrombosis in a patient with combined thrombophilic disorder, complicated by warfarin-induced liver damage Hirmerová J*, Mecová E, Chudáček Z


Patient relationship to the oral anticoagulant therapy with regard to the age, level of education and duration of treatment Vukelíc-Damijanić N*, Caser L, Skalamera R, Vujaklija-Stipanović K


Importance of continuous education in anticoagulated patients Iriarte J*, Longa M, Zorraquin A, Santos M, Vacas M, Narvaez I, Sabino E, Gandarias JM, Saez Y, Saez de Lafuente J
A new approach to identify blood sample collected from hospitalized patients receiving anticoagulant therapy
Katz B, Kirgner I*, Eidelman L, Zwang E, Vardimon H, Goncharov I, Mar-Zev F, Deutsch V

Prolonged increase of plasma vitamin K2 concentration by natto (Bacillus subtilis natto) ingestion
Yatagai C, Yanagisawa Y, Ohsugi T, Sumi H*

How does age influence the prescribing of antithrombotic therapy for ambulatory patients with permanent atrial fibrillation?
Leizorovicz A*, Guenoun M, Le Heuzey J, Jeandel C, Mismetti P, Cohen A

Animal experimental models
Surface-expressed mediators on activated platelets are required for pulmonary leukocyte recruitment in a murine model of allergic inflammation
Pitchford S*, Giannini S, Momi S, Casali L, Gresele P

Activated platelets induce APC-resistance in vivo
Leone M, Momi S, Colucci M, Gresele P*

The thrombolytic effect of longolysin in external application in rabbits
Tamara S, Lidia P, Tamara S, Rosa M, Leonid N, Galina A

Antithrombotic effects of BAY 59-7939, an oral, direct Factor Xa inhibitor, in models of thrombosis and bleeding time in rats and rabbits
Perzborn E*, Buetehorn U, Lampe T, Pernerstorfer J, Pohlmann J, Roehrig S, Schlemmer K, Straub A

Pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rats and dogs

The assessment of MDA and SOD after the administration of Allopurinol in the Ischemia-reperfusion syndrome of the small bowel
Sapalidis K, Makris P*, Girtovitis F, Anestakis D, Deligiannnidis N, Gamvros O

The postoperative inflammatory reaction (IR) in dependence of using different surgical scalpels in experiment
Tatyana S, Ludmila L, Margarita K, Ospan M, Galina A

The formation of stable prethrombotic state is result in an action of different psychostimulators
Tamara S*, Lidiya P, Kira N, Victoria S, Galina A

Cancer and thrombosis
Determination of coagulation inhibitor activity and resistance to activated protein C in non-small cell lung cancer patients (NSCLC)

Angioplasty (ANG) And Anticoagulation (ATC) In Superior Vena Cava Syndrome (SVCS)
Celebrin L*, Carlevaro O, Bluguermann J, Mauro D, Bezares R, Antonio D, Parisi F

Chemotherapy-induced activation of haemostasis: the role of D-dimer

Coagulation derangements in oral and maxillofacial surgery in patients with a documented cancer: a follow-up study after surgery
De Lucia D*, Napolitano M, Misso M, Tagliaferri A, De Francesco F, Borriello C, Colella G

Endothelial cells
Endothelial damage/dysfunction and thrombogenesis in diabetes: positive effects of multifactorial intervention
Lim S*, Blann AD, Lip G

Inhibitory mechanisms of YC-1 and PMC in the induction of iNOS expression by lipoteichoic acid in RAW 264.7 macrophages
Hsiao G*, Huang H, Sheu J

An improved assay for the enumeration of circulating endothelial cells
Woywodt A*, Goldberg C, Scheer J, Regelsberger H, Haller H, Haubitz M

Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem-cell transplantation

Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells
Blann AD*, Makin A, Chung N, Silverman S, Lip G

Hemorheology, hemostasis and antiaggregative activity of endothelium in patients with borderline hypertension
Maximova M*, Ionova V, Suslina Z, Tanashian M, Lutova L, Karabasova M
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene expression profiling of endothelial cells from normal and systemic sclerosis patients</td>
<td>PO069</td>
</tr>
<tr>
<td>Comparison of platelets' and endothelium function between diabetics and normal subjects</td>
<td>PO070</td>
</tr>
<tr>
<td>The evaluation of dysfunction of endothelium in patients with hypertensive small deep infarcts</td>
<td>PO071</td>
</tr>
<tr>
<td>Maximova M*, Suslina Z, Ionova V, Tanashian M</td>
<td></td>
</tr>
<tr>
<td>Direct thrombin inhibitors</td>
<td></td>
</tr>
<tr>
<td>The influence of melagatran on thrombin generation, comparison with other anticoagulant drugs</td>
<td>PO072</td>
</tr>
<tr>
<td>Al Dieri R*, Hemker H, Béguin S</td>
<td></td>
</tr>
<tr>
<td>Melagatran is efficiently eliminated by hemodialysis in uremic patients</td>
<td>PO073</td>
</tr>
<tr>
<td>Eriksson UG, Samuelsson O, Attman PO, Lepkowska M, Ohlsson L, Carlsson S, Fager G</td>
<td></td>
</tr>
<tr>
<td>No influence of food on the pharmacokinetics, pharmacodynamics, or tolerability of the 36mg oral tablet formulation of ximelagatran</td>
<td>PO074</td>
</tr>
<tr>
<td>Ersdal E*, Schützer K, Eriksson UG, Lönnerstedt C, Ohlsson L, Wall U</td>
<td></td>
</tr>
<tr>
<td>Efficacy and safety of postoperative ximelagatran for prevention of thromboembolism across different orthopaedic surgery patient groups</td>
<td>PO075</td>
</tr>
<tr>
<td>Effect of the oral, direct Factor Xa inhibitor, BAY 59-7939, on thrombin generation after tissue factor pathway activation</td>
<td>PO076</td>
</tr>
<tr>
<td>Gerotziafas G*, Depasse F, Chakroun T, Elalamy I, Samama M</td>
<td></td>
</tr>
<tr>
<td>Studies on the mechanism of action of BAY 59-7939 - an oral, direct Factor Xa inhibitor</td>
<td>PO077</td>
</tr>
<tr>
<td>Effects of BAY 59-7939, an innovative, oral, direct Factor Xa inhibitor, on thrombin generation in healthy volunteers</td>
<td>PO078</td>
</tr>
<tr>
<td>Biochemical and pharmacologic properties of BAY 59-7939, an oral, direct Factor Xa inhibitor</td>
<td>PO079</td>
</tr>
<tr>
<td>Multiple dose escalation study investigating BAY 59-7939 - an oral, direct Factor Xa inhibitor - in healthy male subjects</td>
<td>PO080</td>
</tr>
<tr>
<td>Kubitz D*, Becka M, Wensing G, Voith B, Zuehlisdorf M</td>
<td></td>
</tr>
<tr>
<td>Single dose escalation study of BAY 59-7939 - an oral, direct Factor Xa inhibitor - in healthy male subjects</td>
<td>PO081</td>
</tr>
<tr>
<td>Kubitz D*, Becka M, Wensing G, Voith B, Zuehlisdorf M</td>
<td></td>
</tr>
<tr>
<td>The oral direct thrombin inhibitor ximelagatran shows bioequivalence when administered as whole or crushed tablets or in solution via nasogastric tube</td>
<td>PO082</td>
</tr>
<tr>
<td>Schützer K*, Lönnerstedt C, Wall U, Ohlsson L, Sarich T, Teng R, Eriksson UG</td>
<td></td>
</tr>
<tr>
<td>The pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran when administered with erythromycin</td>
<td>PO083</td>
</tr>
<tr>
<td>Doran H*, Schützer K, Sarich T, Wall U, Ohlsson L, Eriksson UG</td>
<td></td>
</tr>
<tr>
<td>Lipoproteins and haemostasis</td>
<td></td>
</tr>
<tr>
<td>Effect of malondialdehyde modified low density lipoproteins on platelet adhesion</td>
<td>PO084</td>
</tr>
<tr>
<td>Suttnar J*, Otahalova E, Dyr JE, Cermak J</td>
<td></td>
</tr>
<tr>
<td>Lipoprotein (a) as a marker of diffuse coronary artery disease in young survivors of myocardial infarction</td>
<td>PO085</td>
</tr>
<tr>
<td>The effect of the new Russian food supplement “Eiferol” on the hemostasis and lipid metabolism in patients with disease of the liver</td>
<td>PO086</td>
</tr>
<tr>
<td>Vjacheslav I*, Valentina P, Galina A, Margarita K, Ludmila L</td>
<td></td>
</tr>
<tr>
<td>Atorvastatin affects thrombosis/fibrinolysis system during the acute phase of unstable angina</td>
<td>PO087</td>
</tr>
<tr>
<td>Kotsopoulou M*, Bosnakou E, Tousoulis D, Antoniades C, Fostira E, Pitsavos C, Stefanadis C</td>
<td></td>
</tr>
<tr>
<td>Effects of atorvastatin on thrombosis/fibrinolysis system and endothelial function, in patients with heart failure</td>
<td>PO088</td>
</tr>
<tr>
<td>Kotsopoulou M*, Antoniades C, Tousoulis D, Bosnakou E, Cheimona A, Pitsavos C, Stefanadis C</td>
<td></td>
</tr>
</tbody>
</table>
**Fibrinolysis**

**The t-PA and PAI-1 activities under treatment by thrombolytic and anticoagulant medicaments in patients with acute myocardial infarction**

Krasnobryzha I*, Savchuk O

**Relationship between global fibrinolytic capacity and cardiovascular risk factors in obese patients**

Turgut B, Guldenen S, Demir M*, Uğur-Altun B, Gerenli M, Vural O, Tugrul A

**Tissue plasminogen activator plasma levels is an independent predictor of in-hospital major events in patients with unstable angina**


**D-dimer promotes endothelial dysfunction in diabetes mellitus**

Yevdokimova N*, Lugovskij E, Komisarenko S

**Pretreatment PAI-1 levels and streptokinase thrombolysis in Iranian patients with acute MI in spite of negligible antistreptokinase antibodies**

Shemirani H*, Tajmirriahi, Rezaei A, Oresi A

**Elevated levels of methylglyoxal may contribute to the development of thrombosis complications in diabetes mellitus**

Léránt I*, Kolek K, Machovich R

**Plasma flow velocity and fibrin specificity of thrombolytic agent promote thrombolysis of non-retracted and retracted whole blood clots**

Tratar G*, Blinc A, Štrukelj M, Mikac U, Šešija I

**Coagulation/fibrinolysis system parameters are affected by smoking cessation**


**Plasminogen Activator Inhibitor (PAI) 4G/5G polymorphism in patients with coronary artery disease**


**The relationship between Ins/Del (I/D) polymorphism in ACE gene with t-PA I/D and PAI-1 4G/5G polymorphisms in PE**

Altinok B*, Öner F, Numanoglu N, Oguzulgen K, Ekim N, Akar N

**PAI-1 levels, 4G/5G genotype and insulin resistance in severe and morbid obesity. Effect of weight loss and influence of 4G/5G genotype**


**Haemostasis activation markers**

Poster withdrawn
The aPTT paradox of the bridging process
Volteas S*, Bossinakou I, parigoti A, Kalatzopoulos D, Matheou S, Nikolaeas M, Sikiotis K

PO114

Pharmacoeconomic analysis of heparin vs. enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery
Honaroro J, Gómez-Outes A*, Navarro-Quilis A, Martinez-González J*, Rocha E, Planés A

PO115

Comparative profile of tinzaparin and a sulfaminoheparosan of bacterial origin: a possible potential alternate for low molecular weight heparins
Maddineni J*, Manoni M, Cornelli U, Hoppensteadt D, Fareed J

PO116

Partial results of the incidence of heparin induced thrombocytopenia
Oliveira S, Rached R*, Caulheiro-Filho C, Chamone D

PO117

Confirmation of the pathogenic role of Ig M and Ig A anti-heparin-PF4 antibodies in patients with heparin-induced thrombocytopenia
Tardy-Poncet B*, Tardy B, Piot M, Reynaud J, Campos L, Decousous H

PO118

Inflammation

PO119

PO120

PO121

PO122

PO123

PO124

PO125

Lupus anticoagulants

Circulating plasma levels of annexin V in venous thromboembolism (VTE)
González-Ordoñó A*, Macías D, Arias A, Ramas C, del Blanco JM, Morán M

PO126

Lupus ratio (LR) and correction ratio (CR) applying to dRVVT results
Gennari L, Blanco A*, Grosso S, Dominguez M, Lazzari M

PO127

Antiphospholipid antibodies in young women without autoimmune diseases and suffering from arterial or venous thromboses
Salobir B*, Šabovič M, Hoinik M, Čučnik S, Kveder T

PO128

Autoantibodies to B2GPI/OxLDL complexes: a novel risk factor for thromboembolic disease in systemic lupus erythematosus?
Lopez L*, Garcia De La Torre I, Matsuura E

PO129

Protein C inhibitor, isolated together with β2-glycoprotein I (β2GPI). A possible player in anti-β2gpi antibody mediated thrombosis?
Čučnik S*, Rozman B, Kveder T, Božič B

PO130

Thrombosis risk in systemic lupus erythematosus
Sallai K*, Nagy E, Gergely P, Bodó I

PO131

Management of pregnancy in patients with autoimmune diseases and antiphospholipid syndrome
Makatsaria A*, Muravieva I, Kusainova V

PO132

Prediction value of several functional examinations for the identification of antiphospholipid-antibody syndrome
Pecka M*, Maly J, Slezakova E, Dulicek P

PO133

Antiphospholipid antibodies enclosed to diagnosis of venous thrombosis
Kostovska S, Neceva V*, Pockova L, Pejceva J, Dejanova V

PO134

Methods in coagulation

PO135

PO136

PO137

PO138

Effect of platelet factor 4 on laboratory tests of the protein C system
Van Dreden P*, Rousseau A, Woodhams B

PO137

Influence of fibrin polymerization on citrated whole blood thromboelastography profile
Chakroun T, Gerotziafas, Samama M, Elalamy I*

PO138
Is the Light Cycler- real time PCR as reliable as the conventional PCR? Our experience
Saour T, Sheereen A, Saour B, Saour J, Mammo L

**PO139**

Evaluation of the Dialab APC Sensitivity Assay
Coen D*, Milos M, Zadro R

**PO140**

A practical von Willebrand disease screening method using ELISAs
Whittier A*, Andrews J, Fink C, Lopez L

**PO141**

**Perinatal and paediatric haemostasis**

Illoemoral deep vein thrombosis in childhood; developing a management protocol
Brightwell R*, Osmani I

**PO142**

Prothrombin gene 20210 G→A heterozygote mutation in a patient with multiple thrombosis - a case report
Ileri T*, Uysal Z, Azik F, Ertem M, Akar N, Kologlu M, Dindar H, Gozdasoglu S

**PO143**

Study of haemostasis in neonates with intrauterine growth retardation (IUGR)

**PO144**

Is long term prophylaxis in pediatric stroke necessary?
Unal O, Uysal Z, Ocal G, Akar N, Deda G*

**PO145**

Cervical artery dissection: long term outcome after anticoagulant therapy
Quintavalla R*, Paganelle E, Paccio C, Rossetti A

**PO146**

Homocysteine in pediatric patients with migraine
Katsadze Y*, Tadieva Z, Shmeleva V

**PO147**

Frequency and association between polymorphism MTHFR gene, folic acid, vitamin B12 and mild hyperhomo-cysteinemia in pediatric stroke

**PO148**

The role of cathepsin G (N125S) and TNF-(-308G/A) polymorphisms in the Turkish pediatric cerebrovascular attack (CVA) patients
Hasipek M*, Karahan Z, Deda G, Akar E, Akar N

**PO149**

Homozygous factor V G1691A mutation in Turkish children with thrombosis
Ulu A, Yildiz Z, Akar E*, Akar N

**PO150**

Prothrombin G20210A and A19911G in Turkish pediatric stroke patients
Yildiz Z*, Akar N, Deda G

**PO151**

Successful immune tolerance therapy with vWF/FVIII concentrate in a hemophilic child with inhibitor
Unuvar A*, Saribeyoglu E, Anak S, Devecioglu O

**PO152**

Alterations of coagulation pathway parameters in children with sickle cell disease (SCD)

**PO153**

The role of inherited hypercoagulable abnormalities in pediatric hematopoietic stem cell transplantation
Ertem M*, Azik F, Ileri T, Akar E, Ulu A, Akar N

**PO154**

Importance of HDL-Cholesterol determination for the diagnosis of hypercholesterolemia during childhood

**PO155**

Thrombogenic parameters in hypercholesterolemic children

**PO156**

TFPI -33T→C polymorphism in Turkish children with cerebral infarct
Donmez BN*, Deda G, Sipahi T, Çaksen H, Cin Ş, Akar N

**PO157**

Body mass index and atherothrombotic risk factors during childhood

**PO158**

FXIII Val34Leu gene polymorphism in Turkish children with cerebral infarct
Donmez BN*, Deda G, Akar N

**PO159**

Deficiency of coagulation inhibitors in children with ischemic stroke and transient ischemic attack (TIA)
Lenicek Krleza J*, Coen D, Zadro R, Stavljenic-Rukavina A

**PO160**

Thromboembolic complication in children with oncologic disease - review of two cases
Vukelic-Damijani N*, Smokvina M, Caser L, Vujaklija-Stipanović K

**PO161**

Platelets

Normal ranges with PFA-100 (Dade-Behring) in healthy subjects

**PO162**

Function of platelets: comparison of findings between the PFA-100 and the aggregometer in normal subjects
Makris P*, Bouktou A, Sarridou D, Papamichos S, Tsokas D, Bougiouklis D, Zarkakoupis A, Papageorgiou I, Anestakis D, Girtovitis F

**PO163**

PADA - Fast and quantitative monitoring of blood platelet adhesiveness
Nowak G*, Bucha E, Wiesenbug A, Schumann A

**PO164**
Poly-APS induced thrombocyte aggregation is partly blocked by the combination of acetylsalicylic acid, clopidogrel and abciximab
Suput D, Bunc M*

Influence of platelet activation agonists on lymphocyte-platelet adhesion
Solpov A*, Vitkovsky Y, Kuznik B

Influence of recombinant interleukin 2 on platelet aggregation and lymphocyte-platelet adhesion
Vitkovsky Y*, Solpov A, Kuznik B

The severity of peripheral arterial disease can influence plasma platelet microparticle levels
Tan K, Tayebjee M, Blann AD*, Lynd C, Lip G*

Patients with stable ischaemic heart disease have increased levels of platelet microparticles
Tan K, Tayebjee M, Blann AD*, Lip G*

Prevalence of aspirin resistance in cardiovascular patients using the PFA-100 diagnostic system

Clinical effects of combined tirofiban with LMWH in patients with acute coronary syndrome

Thrombocytopenia in the intensive care unit. Case series

Salvage plasmapheresis in case of pulmonary embolism caused by heparin-induced thrombocytopenia type II resistant to danaparoid sodium and lepirudin

Pregnancy, menopause, hormones
Prospective study of coagulability in pregnancy - a new approach to the early detection of preeclampsia and cardiovascular complications
Sylvest Andersen A*, Berthelsen JG, Breindahl M, Fareed J, Rud Lassen M

No need for laboratory monitoring during low dose LMMH thromboprophylaxis during pregnancy
van Rosjzen M*, Nistel D, Lampen Mondzo K, Bremme K

Factor VIII levels in the early postpartum period
Procházková J, Procházková J, Králová V, Zelina P

Polymorphism of gene PAI-1 4G/4G and preemorrhagic losses
Bitsadze VO*, Baimuradova SM, Makatsaria A

Acute vascular violations in pregnant women with thrombophilias
Bitsadze VO*, Baimuradova SM, Stuleva N, Makatsaria A

The effects of oral hormone replacement therapy on C-reactive protein and other inflammatory markers in women with previous venous thromboembolism
Eilertsen A*, Hoibraaten E, Sandvik L, Opstad

Estrogen receptors and venous thrombosis
Aléssio AM, Höehr N, Nogueira C, Mansur A, Ozello M, Siqueira L, Annichino-Bizzacchi J M*

The effect of norethisterone acetate on inflammatory markers in postmenopausal women receiving estradiol
Žegura B*, Gužić-Salobir B, Šebestšen J, Meber I, Koenig W

Thrombophilic mutations as inherited risk factors for myocardial infarction in postmenopausal women
Sirotkina O*, Smirnova N, Rodygina T, Toperverg O, Churina S, Schwarzman A

Thrombophilia
Heterozygous Factor V Leiden deficiency with venous thrombosis and pulmonary embolism in a woman with breast cancer

Coagulation studies in patients with thrombosed prosthetic heart valves and intracardiac clots

Thrombosis and familial thrombophilia registry, preliminary report
Mammo L*, Saour T, Hawari S, Sidiqui K, Shereen A, Saour B, Saour J

Frequency of hereditary thrombophilia in Egypt population
Ulu A*, Elsayed S, Yildiz Z, Cin S, Elsobky E, Akar N

Prothrombin G20210A mutation in patients with cerebrovascular disease
Ulutin T, Altinisik J, Somay G, Buyru N

Thrombosis and familial thrombophilia registry, preliminary report
Mammo L*, Saour T, Hawari S, Sidiqui K, Shereen A, Saour B, Saour J

Frequency of hereditary thrombophilia in Egypt population
Ulu A*, Elsayed S, Yildiz Z, Cin S, Elsobky E, Akar N

Prothrombin G20210A mutation in patients with cerebrovascular disease
Ulutin T, Altinisik J, Somay G, Buyru N

Prothrombin G20210A mutation and association with severe life threatening thrombosis among thrombophilic patients
Thrombosis associated with multiple hereditary prothrombotic risk factors and sepsis

Thrombophilia markers in venous thrombotic events
Canak V, Povazan L, Mitic G, Gnip S, Latinovic O

Case report of a family with inherited combinatorial deficiency of protein C and antithrombin III
Trajkov A, Kostovska S*, Neceva V*, Pejceva J, Dimovska N

Combined congenital thrombophilia and essential thrombocytopenia in patients with recidivous pulmonary embolisms and myocardial infarction

The role of PT 20210 G-A, FVL 1691 G-A and FV 4070 A-G as thrombotic risk factors in the development of idiopathic sudden hearing loss
Yildiz Z*, Incesulu A, Ozkaptan Y, Akar N, Tekin M

Factor V Leiden mutation and blood coagulation at the site of microvascular injury in healthy and anticoagulated subjects
Undas A*, Brzezinska-Kolarz B, Iwaniec T, Brozcek J, Musial J

VTE
Effects of enoxaparine for prevention of thrombosis and thromboembolias in patients with chronic heart failure
Olbinskaya L, Kochkareva J, Kolossova K

Multicentric, observational, cross-sectional study to evaluate the VTE risk factors and venous thromboprophylaxis use: a pilot study

Thrombotic complications of peripherally inserted central catheters: a one year retrospective study
Perron S*, Miron M

True incidence of arterial and venous thromboembolic events in the THA patient?
Ryg C*, Rud Lassen M, Solgaard S, Sonne Holm S, Borris L

Epidemiology of post-operative venous thromboembolism in Asian countries: preliminary results of the SMART venography study
Leizorovicz A*, Study Group

Thrombolytic therapy in patients with phlegmasia cerulea dolens
Tardy B*, Moulin N, Mismetti P, Decousus H, Laporte S

Management of thrombophlebitis with two-layer short-stretch bandages
Planinshek Ručigaj T*, Košiček M

Haemorheological and haemostatic alterations in patients with Idiopathic Sudden Sensorineural Hearing Loss

Thrombotic complication treated with defibrotide followed by central nervous system failure in a child after bone marrow transplantation

Residual venous obstruction in patients with a single episode of deep vein thrombosis (DVT) and in patients with recurrent DVT
Dentali F*, Ageno W, Galli M, Mera V, Manfredi E, Steidl L, Venclova A

Hydrofibre dressing versus ointments in the treatment of venous leg ulcers
Košiček M*, Planinshek Ručigaj T

The floating thrombus: a fictitious actor on thromboembolic set (considerations about a clinical case)
Lo Pinto G*

The influence of advanced age and immobility on physician practices for prescribing venous thromboembolism prophylaxis to medical patients
Decousus H*, Tapson V, Chong B, Merli G, Kakkar A, FitzGerald G

Prevention of venous thromboembolism: evaluation of the use of thromboprophylaxis guidelines in a teaching hospital
Grand B*, Duarte P*, Orlos J, Gutierrez R, Oscar M, Riveros D*

Evaluation of the symptoms of acute venous thromboembolism
Rached R*, De Piano L, Cavalheiro C, Chamone D

Progressive versus decreasing elastic stockings in patients presenting with mild venous insufficiency: a randomised clinical trial
Coutzen S, Assante C, Pouget J, Prufert M, Laporte S, Mismetti P*